In 1999 Jamie founded ALS TDI, the world's first nonprofit biotechnology company where he served as CEO until 2007. Under Jamie's leadership ALS TDI pioneered an open research model and an industrialized therapeutic validation process while growing the worlds largest ALS research program. ALS TDI's results have implications far beyond ALS, as the program revealed that much of the positive preclinical studies in the field are a result of noise in the data rather than actual discoveries. ALS TDI is now working on a comprehensive discovery program to find new pathways for treating ALS and is the leading preclinical discovery program.

In 2005 Jamie co-founded PatientsLikeMe with his brother Ben and friend Jeff Cole. Named one of the "15 companies that will change the world" by CNN Money, PatientsLikeMe is a personalized research platform that allows patients, pharmaceutical and biotech companies, and nonprofits to better understand disease, improve individual care and accelerate the development of new treatments and biomarkers. PatientsLikeMe allows patients with ALS, Parkinson's, MS, HIV, Depression, Anxiety, and other mood conditions to share in-depth information on treatments, symptoms, and manage their disease. PatientsLikeMe is rapidly expanding into new indications and developing tools to meaningfully measure outcomes in all long-term illness.

Currently Jamie serves as Chairman of PatientsLikeMe where he is focused on developing a broad patient-centered platform that improves medical care and accelerates the research process by measuring the value of treatments and interventions in the real world.

Jamie's work has been profiled in the New Yorker, New York Times Magazine, 60 Minutes, Pulitzer Prize winner Jonathan Wiener's book, His Brothers Keeper, and the Sundance award winning documentary So Much So Fast.